Information Provided By:
Fly News Breaks for May 14, 2019
May 14, 2019 | 12:31 EDT
Barclays analyst Geoffrey Meacham said he thinks the selloff in shares of Myovant Sciences (MYOV) is overdone after the release of relugolix phase 3 uterine fibroids data. He believes investors are "selling the news" and he still believes relugolix has a comparable profile to AbbVie (ABBV) and Neurocrine's (NBIX) elagolix and will find a place in the market given what he sees as positive data reported this morning, Meacham tells investors. He keeps an Overweight rating and $25 price target on Myovant shares, which are down 26% to $12.67 in early afternoon trading.
News For MYOV;ABBV;NBIX From the Last 2 Days
There are no results for your query MYOV;ABBV;NBIX